Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands

Q2 Pharmacology, Toxicology and Pharmaceutics Current Protocols in Pharmacology Pub Date : 2016-09-16 DOI:10.1002/cpph.12
Andrew Alt
{"title":"Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands","authors":"Andrew Alt","doi":"10.1002/cpph.12","DOIUrl":null,"url":null,"abstract":"<p>Allosteric ligands modulate the activity of receptor targets by binding to sites that are distinct from the orthosteric (native agonist) binding site. Allosteric modulators have potential therapeutic advantages over orthosteric agonists and antagonists, including improved selectivity, and maintenance of the spatial and temporal fidelity of native signaling patterns. The identification of allosteric ligands presents unique challenges because of the requirement for screening in the presence of an orthosteric agonist, the small signal window that is produced by many allosteric modulators, the proclivity of allosteric modulators to exhibit activity switching within a chemotype (e.g., one compound may be a positive allosteric modulator while a close analog is a negative allosteric modulator), and probe dependence (differential interactions with different orthosteric agonists). Described in this unit are emerging strategies for the identification of allosteric ligands by high-throughput screening (HTS), including the use of multiple-add/multiple-read HTS assays and tool molecule-based screening formats. © 2016 by John Wiley &amp; Sons, Inc.</p>","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpph.12","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpph.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 6

Abstract

Allosteric ligands modulate the activity of receptor targets by binding to sites that are distinct from the orthosteric (native agonist) binding site. Allosteric modulators have potential therapeutic advantages over orthosteric agonists and antagonists, including improved selectivity, and maintenance of the spatial and temporal fidelity of native signaling patterns. The identification of allosteric ligands presents unique challenges because of the requirement for screening in the presence of an orthosteric agonist, the small signal window that is produced by many allosteric modulators, the proclivity of allosteric modulators to exhibit activity switching within a chemotype (e.g., one compound may be a positive allosteric modulator while a close analog is a negative allosteric modulator), and probe dependence (differential interactions with different orthosteric agonists). Described in this unit are emerging strategies for the identification of allosteric ligands by high-throughput screening (HTS), including the use of multiple-add/multiple-read HTS assays and tool molecule-based screening formats. © 2016 by John Wiley & Sons, Inc.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
设计和执行高通量变构配体筛选的关键参数概述
变构配体通过结合不同于正构(天然激动剂)结合位点的位点来调节受体靶点的活性。变构调节剂比正构激动剂和拮抗剂具有潜在的治疗优势,包括提高选择性和维持天然信号模式的时空保真度。变构配体的鉴定面临着独特的挑战,因为需要在正构激动剂存在的情况下进行筛选,许多变构调节剂产生的小信号窗口,变构调节剂在化学型中表现出活性切换的倾向(例如,一种化合物可能是正变构调节剂,而接近的类似物可能是负变构调节剂)。探针依赖性(与不同正位激动剂的不同相互作用)。本单元介绍了通过高通量筛选(HTS)鉴定变构配体的新兴策略,包括使用多次添加/多次读取HTS检测和工具分子筛选格式。©2016 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Protocols in Pharmacology
Current Protocols in Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Targeted Protein Degradation Phenotypic Studies Using HaloTag CRISPR/Cas9 Endogenous Tagging Coupled with HaloPROTAC3 Preclinical Models for Studying the Impact of Macrophages on Cancer Cachexia In Vitro Permeation Test (IVPT) for Pharmacokinetic Assessment of Topical Dermatological Formulations Issue Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1